Evidence supports the involvement of 2 common dyslipidemias-low high-density lipoprotein disorders and Lp(a) lipoprotein excess—in coronary heart disease. Until clinical trials determine whether specific therapeutic interventions can prevent the occurrence and recurrence of coronary heart disease in patients with these dyslipidemias, the implementation of cholesterol-lowering guidelines can provide a reasonable way to manage low highdensity lipoprotein disorders and to identify specific categories of patients who may be at particularly high risk for premature coronary heart disease. Empiric treatment guidelines are suggested for low high-density lipoprotein disorders and Lp(a) lipoprotein excess in order to foster further discussion and validation by clinical trial data.
(Arch Intern Med. 1996;156:1278-1284)
Rosenson RS. Beyond Low-Density Lipoprotein CholesterolA Perspective on Low High-Density Lipoprotein Disorders and Lp(a) Lipoprotein Excess. Arch Intern Med. 1996;156(12):1278–1284. doi:10.1001/archinte.1996.00440110036006